ALKEM LABORATORIES LTD.
Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.
• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

13th February, 2026

To,

The Corporate Relationship Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. ***Scrip Code: 539523***	**National Stock Exchange of India Limited** Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. ***Scrip Symbol: ALKEM***

Sub: Press Release

Dear Sir(s) / Madam,

With reference to relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the press release on Alkem MedTech Pvt Ltd ("Alkem MedTech"), a wholly-owned medical devices subsidiary of the Company announces strategic intent to acquire majority stake in Occlutech Holding, Switzerland and the same will be uploaded on the website of the Company.

Kindly take a note of the same.

Sincerely,
For **Alkem Laboratories Limited**

MANISH NARANG
Digitally signed by MANISH NARANG
Date: 2026.02.13 14:31:06 +05'30'

Manish Narang
President - Legal, Company Secretary & Compliance Officer

Encl.: a/a

Press Release

Alkem MedTech announces strategic intent to acquire majority stake in Occlutech Holding, Switzerland

Mumbai, February 13, 2026: Alkem MedTech Pvt Ltd ("Alkem MedTech"), a wholly-owned medical devices subsidiary of Alkem Laboratories Ltd (BSE: 539523, NSE: ALKEM, "Alkem"), today announced the execution of a binding offer for acquiring a majority stake in Occlutech Holding AG ("Occlutech"), a global medical devices company, headquartered in Switzerland, specialising in minimally invasive cardiac implants.

Alkem MedTech intends to buy up to 55% stake in Occlutech for a consideration of EUR 99.4 million (Approx. INR 1,074 crore)[1], subject to statutory approvals. This acquisition represents a significant step in Alkem MedTech's journey to build a global footprint and enables its entry into advanced cardiovascular devices.

Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure. Occlutech is the second-largest company in Europe in the minimally invasive cardiac implants segment and the third-largest globally. It operates manufacturing and R&D facilities in Germany and Turkey, a global distribution hub in Sweden, and clinical operations in the US.

In calendar year 2025, Occlutech recorded a revenue of EUR 49.4 million (unaudited), representing a 15.7% CAGR over the past three years. Occlutech derives about 85% of its revenue from Europe and the US.

Commenting on this development, B. N. Singh, Executive Chairman, Alkem Laboratories said, *"The acquisition of Occlutech opens up significant opportunities for Alkem MedTech, and reinforces Alkem's long-term vision of becoming a global player in the medical devices industry, replicating its success story in pharma. For Alkem, this step reinforces our broader vision of building strong, sustainable and future-ready businesses with advanced, trusted healthcare solutions that improve patient care."*

Kaustav Banerjee, Chief Executive Officer, Alkem MedTech said, *"Occlutech has established capabilities in structural heart devices, a highly-experienced management team, world class R&D and manufacturing facilities, and strong quality and regulatory framework, which provides a strong foundation for Alkem MedTech to begin its journey in the cardiology segment and support sustainable growth. It gives us entry into high-barrier, high-value markets such as the US, Japan, Germany and other western European markets."*

Tor Peters, Chief Executive Officer, Occlutech, said, *"Over the last 23 years, we have built a company driven by patient centricity and innovation. With Alkem MedTech as our strategic investor, we aim to make an impact together through continuous R&D and innovation programmes, bringing high-quality products to serve unmet needs and tap new markets. We also*

[1] Exchange Rate: EUR/INR - 108

expect cost optimisation synergies that will create value for both organisations. We are confident that Alkem's capabilities and strong foundation in healthcare will support the next growth phase of our journey."

The Boston Consulting Group (BCG) acted as an advisor in this transaction.

The transaction remains subject to entering into definitive agreements, Company's conditions precedent to be fulfilled, authorisation by the statutory authority as part of the control of foreign investments in some of the geographies, as well as the absence of qualified material adverse events. The acquisition is expected to be completed by June 2026 after the regulatory approvals are obtained.

--End--

About Alkem MedTech:

Alkem MedTech Pvt. Ltd. is a wholly owned subsidiary of Alkem Laboratories Ltd., the fifth largest pharmaceutical company in India. Alkem MedTech currently focuses on orthopedic implants for load bearing large joints, supported by state-of-the-art, robotic and automation enabled manufacturing facility in Gujarat, and a strong emphasis on product development. In parallel, Alkem MedTech is expanding into the cardiovascular devices segment with a clear vision to build a strong global footprint in this industry. Alkem MedTech has been Alkem's strategic entry into the medical technology sector, a key growth area for the group.

About Occlutech:

Founded in 2003, Occlutech develops, manufactures, and commercializes minimally invasive cardiac implant devices focused on Congenital Heart Defects, Stroke Prevention, and Heart Failure. With products sold in over 80 countries, Occlutech supports interventional cardiologists worldwide in delivering advanced cardiac care solutions. Headquartered in Switzerland, the company operates manufacturing, R&D, distribution, and clinical functions across Europe and the US.

Contacts

Media:	**Investors:**
Isha Trivedi	Purvi Shah
alkemcorpcomm@alkem.com	purvi.shah@alkem.com
+91-98925 90003	+91-84337 00890